Transplantable cells, tissues & organs for patients
Addressing the Organ Shortage Crisis
Recombinetics’ regenerative medicine division, Makana Therapeutics, offers game-changing innovations in xenotransplantation. Makana’s mission is to transform the lives of patients with organ failure by providing an abundant source of donor organs from genetically engineered pigs that lack “xenoantigens”—molecules that would trigger a rejection response from the human immune system. Makana’s focus on simplified genetics, optimized pig cloning techniques and careful patient selection will streamline product development and result in a product that is safer and more effective than “allotransplantation”—human-to-human organ donor transplantation.
FACING THE FACTS
focusing our work
To combat those realities, Makana Therapeutics is focused on…
our competitive advantage
Innovative Insights + Deep Expertise = Extraordinary Results
Makana’s founder is an accomplished transplant surgeon whose insights from allotransplantation provided the roadmap for our lead program, the triple xenoantigen knockout kidney (TKO kidney).
- Simplified set of genome alterations designed to reduce antibody-mediated rejection that will also improve product safety.
- TKO organ will be coupled with proprietary crossmatch assays to identify patients without pre-existing xenoantigens.
- Focused xenoantigen deletion plus crossmatching has demonstrated the longest life-supporting xenokidney grafts in the pig to non-human primate model.
Makana has deep expertise in pig engineering, including carefully optimized cloning protocols and techniques. And we hold the exclusive license to TKO pig intellectual property—the preferred genotype in the xeno- field.
Makana Target One
Addressing the Greatest Need
The vast majority of those on the organ wait list are waiting for a kidney. With so great a need, this is Makana’s first organ target.
With our proprietary combination of genetics, crossmatch assay and known anti-rejection regimen, we are driving toward our goal of first human transplant by 2022.